Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification

Eur Urol. 2015 Jul;68(1):168-70. doi: 10.1016/j.eururo.2015.02.023. Epub 2015 Mar 9.

Authors

Norma Palma¹, John C Morris², Siraj M Ali¹, Jeffrey S Ross³, Sumanta Kumar Pal⁴

Affiliations

¹ Foundation Medicine, Cambridge, MA, USA.
² Division of Hematology-Oncology, University of Cincinnati Cancer Institute, Cincinnati, OH, USA.
³ Foundation Medicine, Cambridge, MA, USA; Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY, USA.
⁴ Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: [email protected].

PMID: 25766722
DOI: 10.1016/j.eururo.2015.02.023

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Angiogenesis Inhibitors / therapeutic use*
Carcinoma, Transitional Cell / drug therapy*
Carcinoma, Transitional Cell / genetics
Carcinoma, Transitional Cell / secondary
Female
Gene Amplification
Humans
Indazoles
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / secondary
Mutation
Pyrimidines / therapeutic use*
Receptor, Fibroblast Growth Factor, Type 3 / genetics
Sulfonamides / therapeutic use*
Urinary Bladder Neoplasms / drug therapy*
Urinary Bladder Neoplasms / genetics
Urinary Bladder Neoplasms / pathology

Substances

Angiogenesis Inhibitors
Indazoles
Pyrimidines
Sulfonamides
pazopanib
FGFR3 protein, human
Receptor, Fibroblast Growth Factor, Type 3